Skip to main content
Lincoln Pharmaceuticals ltd. logo

Lincoln Pharmaceuticals ltd. — Investor Relations & Filings

Ticker · LINCOLN ISIN · INE405C01035 LEI · 3358004B6OBJNW8RTT10 BSE.NS Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2023-02-09 Regulatory Filings
Country IN India
Listing BSE.NS LINCOLN

About Lincoln Pharmaceuticals ltd.

https://www.lincolnpharma.com/

Lincoln Pharmaceuticals Ltd. focuses on the development, manufacturing, and marketing of a diverse range of therapeutic formulations. The organization operates advanced manufacturing facilities certified by international standards, including WHO-GMP. Its portfolio spans multiple areas such as anti-infectives, cardiovascular, gastrointestinal, respiratory, and pain management. The company is recognized for its research and development initiatives, particularly in Novel Drug Delivery Systems (NDDS). Key offerings include specialized treatments for tinnitus and a wide array of formulations in dosage forms like tablets, capsules, liquid orals, and injectables. It maintains a significant global footprint, supplying products to numerous international markets across Africa, Southeast Asia, and Latin America, supported by a robust distribution network for its extensive healthcare catalog.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2023-02-09 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) informing about a scheduled board meeting on February 9, 2023. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2022. The letter also mentions the closure of the trading window as per SEBI regulations. The document does not contain any financial data or results itself, but is an announcement of an upcoming board meeting where financial results will be approved. The document length is short (2434 characters) and it serves as an intimation or notice rather than a report. Therefore, it fits best under Board/Management Information (MANG) as it announces a board meeting and related compliance information.
2023-01-31 English
Updates
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the reconstitution of various board committees following the cessation of an independent director. It details the new composition of the Audit Committee, Nomination and Remuneration Committee, Corporate Social Responsibility Committee, Stakeholder Relationship Committee, and Risk Management Committee. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in board committee membership, which falls under management or board information disclosures. The document length is under 5,000 characters and is a direct announcement, not a report or presentation. Therefore, the appropriate classification is Board/Management Information (MANG).
2023-01-31 English
Updates
Regulatory Filings Classification · 95% confidence The document is a certificate submitted under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2022. It is addressed to stock exchanges and signed by the company secretary. The document is short (2040 characters) and primarily serves as a confirmation certificate rather than containing financial data or detailed report content. It does not contain financial statements or substantive analysis. Therefore, it is a regulatory filing related to compliance and certification rather than a financial report or announcement of a report. According to the Certification Rule and the Menu vs Meal Rule, this document should be classified as a Regulatory Filing (RNS).
2023-01-06 English
Demise
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges (NSE and BSE) about the demise of an Independent Director of the company. It references Regulation 30 of SEBI (Listing Regulations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an announcement of a board/management change (death of a director), not a report or financial statement. The document length is short (1292 characters), and it is clearly an announcement rather than a report or detailed filing. Therefore, the appropriate classification is Board/Management Information (MANG).
2022-12-05 English
Related Party Transaction
Regulatory Filings Classification · 90% confidence The document text contains only references to omitted pictures and no textual content or financial data. The length is very short (701 characters), and there is no indication of any report content, financial statements, or announcements. Given the absence of substantive text and the presence of only images, this document does not fit into any specific report category. It is best classified as a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous filings that do not fit other categories.
2022-11-24 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.